Structure Therapeutics (NASDAQ:GPCR) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks ...

In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management ...

The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by HC Wainwright & Co. on May 12, 2025. The analyst firm set a price target for $75.00 expecting GPCR to rise to ...

“We anticipate partnership interest in Structure’s oral pipeline, potentially following Ph2b aleniglipron data,” the analyst added as she named GPCR as a “preferred stock” within Citi ...

The GPCRs that Structure focuses on are already addressed by biological drugs and drug candidates, but the company aims to hit them instead with small molecules. GPCR drug research poses several ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day GPCR -1.32% DJIA -0.27% S&P Mid Cap 400 -0.28% Health Care/Life Sciences -0.79% ...